Wang Guo-Qiang, Wan De-Sen, Zhou Zhi-Wei, Pan Zhi-Zhong, Chen Gong, Lu Zhen-Hai, Fang Yu-Jing, Wu Xiao-Jun, Li Li-Ren, Ding Pei-Rong
State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P. R. China.
Ai Zheng. 2007 Apr;26(4):411-4.
BACKGROUND & OBJECTIVE: FOLFOX6 regimen has been used in treating advanced colorectal cancer for a period, but there is no systemic study on FOLFOX6 regimen in treating Chinese colorectal cancer patients with liver metastasis. This study was to evaluate the efficacy of FOLFOX6 regimen on Chinese colorectal cancer patients with liver metastasis, and observe the adverse events.
Ninety-one colorectal cancer patients with liver metastasis were treated by FOLFOX6 regimen. FOLFOX6 regimen consisted of 2-hour infusion of oxaliplatin (100 mg/m(2)) and 2-hour infusion of leucovorin (CF) (400 mg/m(2)) on Day l, followed by 5-fluorouracil (5-FU) bolus (400 mg/m(2)) on Day 1 and 46-hour infusion (2.4 g/m(2)). FOLFOX6 regimen was repeated at 2-week intervals. The clinical efficacy and adverse events were evaluated.
The objective response rate for all patients was 40.7%, with 4 cases of complete remission (CR), 33 partial remission (PR), 19 stable disease (SD), and 35 progressive disease (PD). There was no significant difference in objective response rate between the patients with and without previous treatment (P>0.05). The median survival time was 17.0 months for all patients, 20.0 months for the patients without previous treatment, and 12.0 months for the patients with previous treatment. The time to progress (TTP) was 7.0 months for all patients, 9.0 months for the patients without previous treatment, and 6.0 months for the patients with previous treatment. Peripheral neuritis, gastrointestinal reaction, and myelosuppression were major adverse events. All patients with 5-FU-associated adverse events recovered after treatment.
FOLFOX6 regimen can be used in treating colorectal cancer with liver metastasis for its efficacy and less toxicity.
FOLFOX6方案已用于治疗晚期结直肠癌一段时间，但尚无关于FOLFOX6方案治疗中国结直肠癌肝转移患者的系统研究。本研究旨在评估FOLFOX6方案对中国结直肠癌肝转移患者的疗效，并观察不良事件。
91例结直肠癌肝转移患者接受FOLFOX6方案治疗。FOLFOX6方案包括第1天静脉滴注奥沙利铂（100mg/m²）2小时和亚叶酸钙（CF）（400mg/m²）2小时，随后第1天静脉推注5-氟尿嘧啶（5-FU）（400mg/m²），并持续静脉滴注46小时（2.4g/m²）。FOLFOX6方案每2周重复一次。评估临床疗效和不良事件。
所有患者的客观缓解率为40.7%，其中完全缓解（CR）4例，部分缓解（PR）33例，疾病稳定（SD）19例，疾病进展（PD）35例。既往接受过治疗和未接受过治疗的患者客观缓解率无显著差异（P>0.05）。所有患者的中位生存时间为17.0个月，未接受过治疗的患者为20.0个月，接受过治疗的患者为12.0个月。所有患者的疾病进展时间（TTP）为7.0个月，未接受过治疗的患者为9.0个月，接受过治疗的患者为6.0个月。周围神经炎、胃肠道反应和骨髓抑制是主要不良事件。所有发生与5-FU相关不良事件的患者治疗后均恢复。
FOLFOX6方案因其疗效和较低毒性可用于治疗结直肠癌肝转移。
